» Articles » PMID: 33604313

The Significance of Gamma-Glutamyl Transpeptidase to Lymphocyte Count Ratio in the Early Postoperative Recurrence Monitoring and Prognosis Prediction of AFP-Negative Hepatocellular Carcinoma

Overview
Date 2021 Feb 19
PMID 33604313
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Currently, there is still a lack of effective biomarkers for the recurrence monitoring and survival prognosis assessment of hepatocellular carcinoma (HCC) patients with alpha-fetoprotein (AFP)-negative (≤20 ng/mL) after radical resection.

Methods: The clinicopathological data of 606 patients (303 in the AFP-negative group and 303 in the AFP-positive group) who underwent radical resection of HCC were analyzed retrospectively.

Results: The gamma-glutamyl transpeptidase to lymphocyte count ratio (GLR) of patients in the AFP-negative group was lower than that in the AFP-positive group ( <0.001). The GLR level of the early-recurrence group was higher than that of the non-early-recurrence group ( =0.003). GLR had fair accuracy in predicting the early-recurrence of HCC patients [c-index=0.654 (95% CI=0.606-0.702); AUC=0.681 (95% CI=0.625-0.733)]. Univariate analysis showed that patients with tumor size <5 cm, no microvascular invasion, single tumor, no metastasis, BCLC stage 0-A, no recurrence, and GLR ≤45.0 had longer disease-free survival (DFS) and overall survival (OS) among AFP-negative HCC patients. In addition, multivariate Cox proportional hazards regression analysis showed that tumor size <5 cm ( =0.003), no recurrence ( <0.001), and GLR <45.0 ( <0.001) were independent predictors of longer OS.

Conclusion: GLR may be a potential indicator for early recurrence monitoring and prognosis evaluation in HCC patients with AFP-negative after radical resection.

Citing Articles

Early identification of hepatocellular carcinoma patients at high-risk of recurrence using the ADV score: a multicenter retrospective study.

Cao S, Zhou Z, Chen C, Li W, Liu J, Xu J World J Surg Oncol. 2024; 22(1):240.

PMID: 39244533 PMC: 11380786. DOI: 10.1186/s12957-024-03523-1.


Recurrence of Hepatocellular Carcinoma in Patients with Low Albumin-Bilirubin Grade in TACE Combined with Ablation: A Random Forest Cox Predictive Model.

Xiong Y, Qiao W, Mei T, Li K, Jin R, Zhang Y J Hepatocell Carcinoma. 2024; 11:1375-1388.

PMID: 39005969 PMC: 11245575. DOI: 10.2147/JHC.S465962.


Incorporating Inflammatory Markers and Clinical Indicators into a Predictive Model of Single Small Hepatocellular Carcinoma Recurrence After Primary Locoregional Treatments.

Qiao W, Xiong Y, Li K, Jin R, Zhang Y J Hepatocell Carcinoma. 2024; 11:1113-1125.

PMID: 38887683 PMC: 11182039. DOI: 10.2147/JHC.S465069.


Radiomics model based on contrast-enhanced computed tomography imaging for early recurrence monitoring after radical resection of AFP-negative hepatocellular carcinoma.

Yan X, Li Y, Qin W, Liao J, Fan J, Xie Y BMC Cancer. 2024; 24(1):700.

PMID: 38849749 PMC: 11157869. DOI: 10.1186/s12885-024-12436-x.


DGPRI, a new liver fibrosis assessment index, predicts recurrence of AFP-negative hepatocellular carcinoma after hepatic resection: a single-center retrospective study.

Zhang B, Xue J, Xu B, Chang J, Li X, Huang Z Sci Rep. 2024; 14(1):10726.

PMID: 38730095 PMC: 11087499. DOI: 10.1038/s41598-024-61615-0.


References
1.
Bialecki E, Ezenekwe A, Brunt E, Collins B, Ponder T, Bieneman B . Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006; 4(3):361-8. DOI: 10.1016/S1542-3565(05)00977-8. View

2.
Hu B, Yang X, Xu Y, Sun Y, Sun C, Guo W . Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014; 20(23):6212-22. DOI: 10.1158/1078-0432.CCR-14-0442. View

3.
Perz J, Armstrong G, Farrington L, Hutin Y, Bell B . The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45(4):529-38. DOI: 10.1016/j.jhep.2006.05.013. View

4.
Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C . Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?. Am J Gastroenterol. 2006; 101(3):524-32. DOI: 10.1111/j.1572-0241.2006.00443.x. View

5.
Sohn W, Paik Y, Kim J, Kwon C, Joh J, Cho J . HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma. Ann Surg Oncol. 2014; 21(7):2429-35. DOI: 10.1245/s10434-014-3621-x. View